Navigation Links
Cempra Pharmaceuticals to Present at Two Investor Conferences in Paris
Date:5/18/2011

CHAPEL HILL, N.C., May 18, 2011 /PRNewswire/ -- Cempra Pharmaceuticals Inc. today announced that Prabhavathi Fernandes, Ph.D., president and chief executive officer, will present at two upcoming investor conferences in Paris.  Dr. Fernandes will present at the 18th Annual Euro-Biotech Forum at 9:45 a.m. CET, May 24, at the Hilton Arc de Triomphe.  Dr. Fernandes will later present at BioEquity Europe 2011 at 3:00 p.m. CET, May 24, at the Paris Marriott Rive Gauche.  Dr. Fernandes will provide an overview of the company's two leading antibiotic clinical programs, solithromycin for community-acquired bacterial pneumonia and TAKSTA™ for the oral treatment of gram positive pathogens including methicillin-resistant S. aureus (MRSA).

About Cempra Pharmaceuticals

Founded in 2006, Cempra Pharmaceuticals is a privately held, clinical-stage pharmaceutical company focused on developing antibacterials to address critical medical needs. Two lead products, both in late-stage clinical trials, address the urgent and increasing need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. Cempra is well-funded and is committed to developing commercially and medically differentiated and novel products that reduce development risk and provide a high financial return. The company is also utilizing its proprietary compound library and chemistry technology to develop novel macrolides without antibacterial activity for non-antibiotic uses such as COPD, chronic inflammatory and GI disorders. Additional information about Cempra can be found at www.cempra.com.

Media Contacts:
Robert E. Flamm, Ph.D.
Russo Partners, LLC
(212) 845-4226
Robert.flamm@russopartnersllc.com

Tony Russo, Ph.D.
Russo Partners, LLC
(212) 845-4251
Tony.russo@russopartnersllc.com


'/>"/>
SOURCE Cempra Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intravenous (IV) Administration of Cempra Pharmaceuticals Solithromycin (CEM-101) Demonstrates Excellent Systemic Tolerability in a Phase 1 Clinical Trial
2. Cempra Pharmaceuticals to Present at Two Upcoming Cambridge Healthtech Institute (CHI) Conferences
3. Cempra Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Cempra Expands Clinical Management Team to Advance Leading Antibacterial Clinical Programs Solithromycin and TAKSTA™
5. Cempra Pharmaceuticals Names Carl Foster Executive Vice President of Business Development
6. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
7. Cempra Pharmaceuticals to Present at the UBS Global Life Sciences Conference
8. Cempra Pharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
9. Cempra Pharmaceuticals To Present at the Lazard Capital Markets 6th Annual Healthcare Conference on November 17th
10. Presentations of Cempra Pharmaceuticals CEM-102 (fusidic acid) at the Infectious Diseases Society of America Annual Meeting Highlight Properties That Make It an Excellent Anti-MRSA Candidate
11. Data Presented on Cempra Pharmaceuticals CEM-101 at the Infectious Diseases Society of America Annual Meeting Reinforces Potency and Coverage Against Multidrug-Resistant S. Pneumoniae Isolates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Transformational M&A achieved through NPS and Dyax acquisitions ... Transformational M&A achieved through NPS and Dyax acquisitions and the ... M&A achieved through NPS and Dyax acquisitions and the announced ... with most robust pipeline in Shire , s ... most robust pipeline in Shire , s history ...
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... ALBANY, New York , February 11, 2016 ... Research announces the release of a new research report, titled ... Growth, Trends and Forecast, 2013 - 2019". According to the ... expand at a 4.40% CAGR from 2013 to 2019, growing ... bn by 2019. --> --> ...
Breaking Medicine Technology:
(Date:2/11/2016)... ... February 11, 2016 , ... ... a master charity program created to assist the people of their local community. ... with nonprofit organizations and community leaders. Their hope is to bring awareness to ...
(Date:2/11/2016)... ... February 11, 2016 , ... AccuVein Inc. announces the Infusion ... of Practice, to include vascular visualization as a standard practice. AccuVein ( http://www.accuvein.com ... the market, facilitates adherence to this standard with its easy to use, widely ...
(Date:2/11/2016)... ... February 11, 2016 , ... Duterte Insurance ... involvement program, introduces a new charity campaign to raise funds for Ronald McDonald ... accepted at https://donate.rmhc.org/ . , Ronald McDonald House (RMH) is an internationally ...
(Date:2/11/2016)... ... ... The annual list showcases the 20 Most Promising SharePoint Solution Providers in 2015. ... to the SharePoint ecosystem. A panel of experts and members of CIOReview’s editorial board ... promote technology entrepreneurship. , The survey was made at the end of the ...
(Date:2/11/2016)... (PRWEB) , ... February 11, 2016 , ... Be ... new office in the heart of Old Town at 108 South Columbus St, Suite ... businesses the highest level of medical care in the convenience of their homes, offices ...
Breaking Medicine News(10 mins):